Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Common Equity: 2010-2025

Historic Common Equity for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $920.2 million.

  • Catalyst Pharmaceuticals' Common Equity rose 39.23% to $920.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.2 million, marking a year-over-year increase of 39.23%. This contributed to the annual value of $727.6 million for FY2024, which is 87.59% up from last year.
  • Catalyst Pharmaceuticals' Common Equity amounted to $920.2 million in Q3 2025, which was up 7.50% from $856.0 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Common Equity peaked at $920.2 million during Q3 2025, and registered a low of $178.7 million during Q1 2021.
  • Moreover, its 3-year median value for Common Equity was $608.7 million (2024), whereas its average is $597.7 million.
  • Data for Catalyst Pharmaceuticals' Common Equity shows a peak YoY spiked of 89.63% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Common Equity stood at $206.8 million in 2021, then spiked by 45.25% to $300.4 million in 2022, then climbed by 29.11% to $387.9 million in 2023, then spiked by 87.59% to $727.6 million in 2024, then skyrocketed by 39.23% to $920.2 million in 2025.
  • Its Common Equity stands at $920.2 million for Q3 2025, versus $856.0 million for Q2 2025 and $794.3 million for Q1 2025.